Bortezomib and panobinostat combination is effective against PTCL

Phipps, Colin; Mok, Swee Jin; Ang, Ai Leen; Goh, Yeow Tee; Tan, Daryl

doi:10.1016/j.leukres.2012.02.029

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HDAC inhibitors were reported to have synergistic antitumor activity with mTOR inhibitors based on their mechanisms of action. The combination of Panobinostat with Bortezomib exhibited highly synergistic efficacy against PTCL via inducing polyubiquitinated protein accumulation in preclinical studies, promoting its further exploration in clinical trials 162, 163. In a phase I study of the combination of Panobinostat plus Everolimus in patients with relapsed or refractory Hodgkin and non-Hodgkin lymphoma (T-cell lymphomas included), highly synergistically therapeutic effects were demonstrated, 33% patients (indolent lymphoma, T-cell lymphoma, mantle cell lymphoma, and Hodgkin lymphoma) achieved objective responses and decreased multiple serum cytokine levels 164.…”

Section: Therapeutic Strategies Targeting Hdacsmentioning

confidence: 99%

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

et al. 2019

View full text Add to dashboard Cite

T-cell lymphomas are a heterogeneous group of cancers with different pathogenesis and poor prognosis. Histone deacetylases (HDACs) are epigenetic modifiers that modulate many key biological processes. In recent years, HDACs have been fully investigated for their roles and potential as drug targets in T-cell lymphomas. In this review, we have deciphered the modes of action of HDACs, HDAC inhibitors as single agents, and HDACs guided combination therapies in T-cell lymphomas. The overview of HDACs on the stage of T-cell lymphomas, and HDACs guided therapies both as single agents and combination regimens endow great opportunities for the cure of T-cell lymphomas.

show abstract

Section: Therapeutic Strategies Targeting Hdacsmentioning

confidence: 99%

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

et al. 2019

View full text Add to dashboard Cite

show abstract

“…One ongoing clinical trial is testing the combination of panobinostat and bortezomib in patients with relapsed/refractory PTCL (NCT00901147). A case report described a complete response in one patient with PTCL-NOS from that trial [78].…”

Section: Epigenetic-modifying Agentsmentioning

confidence: 99%

From empiric to mechanism-based therapy for peripheral T cell lymphoma

Intlekofer

Younes

2014

Int J Hematol

View full text Add to dashboard Cite

Peripheral T cell lymphoma (PTCL) represents a heterogeneous group of mature T and natural killer cell-derived neoplasms, comprising approximately 10 % of non-Hodgkin lymphoma. Although at least 20 distinct histologic subtypes of PTCL have been identified, the historical treatment approach has been uniform application of anthracycline-based combination chemotherapy, resulting in significantly inferior outcomes compared to B-cell non-Hodgkin lymphoma. Because of the generally poor outcomes with conventional chemotherapy, PTCL represents an unmet medical need, therefore providing the opportunity to evaluate novel agents. Herein, we will review the evolving treatment strategies for PTCL, discuss how different treatment approaches impact the underlying biology of PTCL, and speculate on future targets for therapeutic intervention. We conclude that future efforts to develop effective therapies for PTCL will benefit from a biomarker-driven strategy rather than histologic classification.

show abstract

Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin

O’Connor

2021

The Peripheral T‐Cell Lymphomas

View full text Add to dashboard Cite

Bortezomib and panobinostat combination is effective against PTCL

Cited by 3 publications

References 3 publications

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas

From empiric to mechanism-based therapy for peripheral T cell lymphoma

Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin

Contact Info

Product

Resources

About